LumiraDx and Chembio announce COVID-19 Strategic Partnership

London, UK, March 12th  2020 - LumiraDx UK Ltd., today announced plans it has entered a strategic partnership with Chembio Diagnostics (Nasdaq: CEMI) to develop point of care test solutions for the detection and monitoring of the COVID-19 virus, and IgG and IgM antibodies. The agreement builds on the strengths of both companies in delivering novel point of care test solutions.

“We are pleased to expand our relationship with Chembio as our partner given the company’s expertise and speed in developing high-quality point of care assays. By joining forces and bringing together the best of these two companies, we believe we will become the chosen approach for the detection and monitoring of the COVID-19 virus, which has become a worldwide pandemic,” stated Ron Zwanziger, LumiraDx's Chairman and Chief Executive Officer.

Point of care test solutions will be developed on both the LumiraDx and Chembio DPP platforms

About the LumiraDx Platform

The LumiraDx Platform is a simple, easy to use, portable point of care test system. Its microfluidic technology enables accurate test results in line with those from hospital laboratory analysers, using small patient samples, including capillary fingerstick blood. Fast results are delivered in minutes at the patient side and can be connected directly into the patient’s health record. The LumiraDx technology is designed to be cost-effective and applicable to many diagnostic assays, with a number of tests already in development and near to launch.  The Platform will develop into a unique connected multi-test solution with the potential to accelerate diagnostic testing to improve clinical decision-making and patient experience, leading to better outcomes.

About LumiraDx

Our smarter connected diagnostics and diagnostic-led care solutions are designed to enable more effective and cost-efficient patient care. The LumiraDx Group was founded in 2014 by entrepreneurs with a successful track record in building and scaling medical diagnostics and health IT businesses. Based in the UK and the USA and supported by a global distribution network, LumiraDx has over 600 employees worldwide.  The company has an experienced senior leadership team, which includes Chief Executive Officer Ron Zwanziger, Chief Scientist Dr Jerry McAleer and Chief Technology Officer Dr Dave Scott.

Further information on the LumiraDx and the LumiraDx Platform is available at

Press Contact:

Dr Jayne Ellis, 
Head of Medical Affairs,